理想汽車-W(02015.HK):公司股份獲納入深港通
格隆匯3月14日丨於2022年3月14日(美國東部時間),中國新能源汽車市場的創新者理想汽車("理想汽車"或"公司")(納斯達克:LI;香港交易所:2015)宣佈,根據深圳證券交易所的公吿,公司於聯交所上市交易的A類普通股於2022年3月14日被納入深港通。
進入深港通有助公司擴大投資者基礎,同時通過金融市場與中國大陸的用户、合作伙伴以及投資者們分享成長軌跡以及日後的進一步成功。
於2021年8月26日,公司獲納入恆生綜合指數及其分類指數(包括恆生綜合大型股指數),並於2022年3月7日獲納入恆生科技指數。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.